ATCC has been selected by ARPA-H to support the BioStabilization Systems (BoSS) program. The program aims to shift cell therapy storage from -196°C to room temperature. Maintaining the cold chain presents significant challenges, including substantial costs and potential product loss due to temperature excursions.
Program Objectives
Reducing reliance on the cold chain could improve affordability, simplify distribution, and increase patient access to cellular medicines. ATCC will provide independent verification and validation (IV&V) for the technologies involved.
ATCC’s Role
Under this arrangement, ATCC will furnish working cell banks and standardized benchmarks to BoSS performers. The organization will independently evaluate emerging stabilization technologies, assessing their preservation of cell quality and performance. Evaluations will focus on reproducibility, scalability, ease of use, and overall suitability. Traceability will be maintained throughout the program’s assessments.
ATCC’s capabilities include authenticated biological materials, scientific expertise, quality infrastructure, and program execution capabilities. The organization’s work will provide objective data to inform ARPA-H’s comparisons of different approaches. This initiative addresses a challenge in expanding patient access to advanced medicine.
Eldar Imanverdi, senior director of Business Development, ATCC Federal Solutions, expressed pride in receiving the initial award from ARPA-H and contributing to the Scalable Solutions Office’s mission. The program represents a high-risk, high-reward research effort with the potential to deliver transformative health solutions.